· Robust resilience in revenues at €4.9 million driven by Theranostic up +16.5% · Continued investment in R&D to drive future growth · North America business accelerates · Sound cash position at €1.7 million · Launch…
Croissy-Beaubourg, September, 16, 2020, 8:00 am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan), a company specializing in in vitro diagnostics and theranostics, is pleased to announce the…
Croissy-Beaubourg, le 7 septembre, 17h45 CEST – THERADIAG (ISIN : FR0004197747, Mnémonique : ALTER), société spécialisée dans le diagnostic in vitro des maladies auto-immunes et le Théranostic publiera ses résultats semestriels consolidés clos au 30 juin…